BI Aggrenox Recommended For Stroke; Mortality Labeling Uncertain
Executive Summary
FDA will consider whether to include information on the potential mortality benefit of Boehringer-Ingelheim's Aggrenox (dipyridamole/aspirin) in labeling after an advisory committee recommended against including a mortality claim among the approved indications for the product.
You may also be interested in...
Boehringer Ingelheim Aggrenox
Dipyridimole and aspirin twice-daily capsules are deemed "approvable" June 15. Extended-release combination was recommended by an FDA advisory committee for reduction in risk of a secondary stroke, but not for reduction of mortality risk (1"The Pink Sheet" May 3, p. 9)
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011